News 
Market Data 
Discover
Replies to post #207806 on Innovation Pharmaceuticals Inc (IPIX)
12/12/17 4:10 PM
12/12/17 5:44 PM
12/12/17 6:36 PM
Example using IPIX B-OM phase2 percentages. Let’s use the low and more conservative 60% for placebo vs the more realistic 75% number seen in previous trials. So if there were 1000 patients being treated with Throat and Neck cancer at least 600 would get OM without any treatment to PREVENT getting OM. If those same 1000 patients did a simple swish and spit 3 times a day with B there would be 368 people that still would get OM meaning 232 of the 600 would NOT GET the OM disease by using B. (Per protocol population of 36.8% so 368 people vs 600 people). Reducing the odds of getting OM by 38.66% (232/600). So using the conservative 60 placebo number B will reduce the chances of GETTING OM by 38.66%. Using a more realistic number of 75% instance of getting OM that number goes from 38.66% to 50.93% PREVENTION rate. If you could reduce your chances of getting a disease that makes it extremely difficult to eat, drink or swallow by 39-51% by doing a simple swish and spit would you do it? If you were a doctor that cared for your patient’s well-being would you subscribe it? BTW, there were ZERO instances of SAE related to B (extremely safe to use). As others have mentioned we haven’t even seen secondary data to see improvements of symptoms using B which is gravy on top of meeting the study’s primary endpoint. I am a retired computer sales guy with zero medical background. Do you think the medical and business people in big pharma with full access to all the data under NDA will figure this out? My money says they will/have.
AI
